BioNTech Management

Management criteria checks 4/4

BioNTech's CEO is Ugur Sahin, appointed in Jan 2008, has a tenure of 16.25 years. total yearly compensation is €3.06M, comprised of 22.9% salary and 77.1% bonuses, including company stock and options. directly owns 17.14% of the company’s shares, worth $3.59B. The average tenure of the management team and the board of directors is 5.3 years and 4 years respectively.

Key information

Ugur Sahin

Chief executive officer

€3.1m

Total compensation

CEO salary percentage22.9%
CEO tenure16.3yrs
CEO ownership17.1%
Management average tenure5.3yrs
Board average tenure4yrs

Recent management updates

Recent updates

We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

Mar 27
We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 24
BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions

Mar 20

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

Feb 23

BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

Feb 09
BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Jan 18
Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

Jan 02
Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Dec 11
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

Oct 22
Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Sep 11
BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Is BioNTech (NASDAQ:BNTX) A Risky Investment?

Jun 13
Is BioNTech (NASDAQ:BNTX) A Risky Investment?

A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)

May 23
A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates

Mar 29
BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates

These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely

Mar 05
These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely

A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)

Feb 18
A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)

Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates

Feb 02
Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates

With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case

Jan 26
With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case

BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%

Nov 19
BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%

BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly

Nov 09
BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly

CDC advisory panel recommends COVID vaccines for children be included in federal program

Oct 19

Do BioNTech's (NASDAQ:BNTX) Earnings Warrant Your Attention?

Oct 18
Do BioNTech's (NASDAQ:BNTX) Earnings Warrant Your Attention?

Hong Kong approves BioNTech COVID vaccine for infants

Oct 12

EMA starts rolling review of Pfizer/BioNTech's Omicron-subvariant adapted shot for kids

Oct 03

BioNTech: A Tale Of 2 Companies

Sep 20

European drug regulator panel backs approval of Pfizer/BioNTech's Omicron-adapted shot

Sep 12

CDC advisors to vote on COVID Omicron vaccines on Sept. 1

Aug 30

CEO Compensation Analysis

How has Ugur Sahin's remuneration changed compared to BioNTech's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023€3m€700k

€930m

Sep 30 2023n/an/a

€3b

Jun 30 2023n/an/a

€4b

Mar 31 2023n/an/a

€6b

Dec 31 2022€6m€360k

€9b

Sep 30 2022n/an/a

€10b

Jun 30 2022n/an/a

€12b

Mar 31 2022n/an/a

€13b

Dec 31 2021€12m€360k

€10b

Sep 30 2021n/an/a

€7b

Jun 30 2021n/an/a

€4b

Mar 31 2021n/an/a

€1b

Dec 31 2020€17m€360k

€15m

Sep 30 2020n/an/a

-€410m

Jun 30 2020n/an/a

-€230m

Mar 31 2020n/an/a

-€192m

Dec 31 2019€7m€311k

-€179m

Sep 30 2019n/an/a

-€122m

Jun 30 2019n/an/a

-€116m

Mar 31 2019n/an/a

-€77m

Dec 31 2018€653k€210k

-€48m

Compensation vs Market: Ugur's total compensation ($USD3.25M) is below average for companies of similar size in the US market ($USD12.85M).

Compensation vs Earnings: Ugur's compensation has been consistent with company performance over the past year.


CEO

Ugur Sahin (58 yo)

16.3yrs

Tenure

€3,056,000

Compensation

Prof. Dr. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board since 2008 and serves as its Chair of the Management Board. Pr...


Leadership Team

NamePositionTenureCompensationOwnership
Ugur Sahin
Co-Founder16.3yrs€3.06m17.14%
€ 3.6b
Ozlem Tureci
Co-Founder6.3yrs€814.00k0.38%
€ 79.5m
Jens Holstein
CFO & Member of Management Board2.8yrs€1.32m0.00067%
€ 140.5k
Sierk Poetting
MD, COO & Member of Management Board10.3yrs€821.00k0.31%
€ 65.7m
Ryan Richardson
Chief Strategy Officer4.3yrs€1.41m0.0061%
€ 1.3m
Sean Marett
Chief Business Officer12.3yrs€133.00k0.34%
€ 70.9m
James Timothy Ryan
Chief Legal Officer & Member of the Management Boardless than a year€848.00kno data
Zach Taylor
Senior Vice President of Corporate Development & Strategyless than a yearno datano data
Katalin Kariko
Senior VP & External Consultant for RNA Protein Replacement Therapiesno datano datano data
Oliver Henning
Senior Vice President of Operationsno datano datano data
Sebastian Kreiter
Senior Vice President of Immunotherapy & Preclinical Researchno datano datano data
Siegbert Kloos
Senior Vice President of Global R&D Digitalno datano datano data

5.3yrs

Average Tenure

56yo

Average Age

Experienced Management: BNTX's management team is seasoned and experienced (5.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Rudolf Staudigl
Supervisory Board Member1.8yrs€90.00k0.00017%
€ 35.6k
Ulrich Wandschneider
Independent Deputy Chairman Supervisory Board6.3yrs€114.00kno data
Michael Motschmann
Independent Supervisory Board Member16.3yrs€80.00kno data
Helmut Jeggle
Independent Supervisory Board Chairman16.3yrs€226.00k0.14%
€ 28.9m
Nicola Blackwood
Member of Supervisory Boardless than a year€46.00kno data
Anja Morawietz
Supervisory Board Member1.8yrs€105.00k0.00010%
€ 21.0k

4.0yrs

Average Tenure

57.5yo

Average Age

Experienced Board: BNTX's board of directors are considered experienced (4 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.